N-Methyl-4-morpholincarboxamidin | 91588-71-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-Methyl-4-morpholincarboxamidin
• 英文别名: N-methyl-morpholine-4-carboximidic acid amide；N'-methylmorpholine-4-carboximidamide
• CAS: 91588-71-5
• 化学式: C₆H₁₃N₃O
• 分子量: 143.189
• InChiKey: XCGCQVZPKPJXMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  50.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  Morpholin-thiocarbonsaeure-(4)-methylamid 生成 N-Methyl-4-morpholincarboxamidin
  参考文献：
  名称：

  Takahashi,K. et al., Chemical and pharmaceutical bulletin, 1963, vol. 11, p. 601 - 604

  摘要：

  DOI：

文献信息

• BOROPEPTIDE INHIBITORS OF ENTEROPEPTIDASE AND THEIR USES IN TREATMENT OF OBESITY, OVERWEIGHT AND/OR DISEASES ASSOCIATED WITH AN ABNORMAL FAT METABOLISM
  申请人：Harosh Itzik

  公开号：US20100311690A1

  公开（公告）日：2010-12-09

  The present invention relates to novel compounds, particularly derivatives of boroarginine, boroornithine and borolysine that selectively modulate, regulate, and/or inhibit enteropeptidase. The invention also relates to compositions, particularly pharmaceutical compositions, as well as methods to treat excess weight, obesity and diseases associated with an abnormal fat metabolism.

  本发明涉及新型化合物，特别是硼精氨酸衍生物、硼鸟氨酸衍生物和硼赖氨酸衍生物，它们能够选择性地调节、调控和/或抑制肠肽酶。本发明还涉及组合物，特别是制药组合物，以及治疗过度体重、肥胖和与异常脂肪代谢相关的疾病的方法。
• SMALL MOLECULE PI 3-KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Nuss John N.

  公开号：US20090060912A1

  公开（公告）日：2009-03-05

  Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.

  提供了化学式I的化合物，其中变量具有所述的值。药物制剂包括该化合物或其药学上可接受的盐以及药学上可接受的载体和其他药物的组合。治疗患者的方法包括向需要该制剂的患者给予本发明的药物制剂。
• 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
  申请人：Fink Anne Cynthia

  公开号：US20070060582A1

  公开（公告）日：2007-03-15

  This invention relates to compounds of the formula (I) wherein the variable substituents are described herein. The compounds are useful for the treatment of conditions and diseases characterized by an aberrant MAP kinase signaling pathway, such as cancer.

  本发明涉及公式（I）中变量取代基的化合物，所述的化合物可用于治疗由异常MAP激酶信号通路引起的疾病和症状，例如癌症。
• Propane-1,3-Dione Derivative or Salt Thereof
  申请人：Hirano Masaaki

  公开号：US20090181964A1

  公开（公告）日：2009-07-16

  It is intended to provide a compound useful as a GnRH receptor antagonist. The inventors further investigated propane-1,3-dione derivatives. As a result, they confirmed that a compound having a benzene ring or a thiophene ring substituted with a group represented by —SO 2 —R 3 in a propane-1,3-dione derivative having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene) has an excellent GnRH receptor antagonistic effect and accomplished the present invention. Because the compound of the present invention has a potent GnRH receptor antagonistic effect, it is useful for the treatment of sex hormone-dependent diseases, particularly GnRH-related diseases. Further, because the compound of the present invention has an excellent metabolic stability in human and few drug interactions, therefore it has preferable characteristics as a pharmaceutical used for the above-mentioned diseases.

  本发明旨在提供一种作为GnRH受体拮抗剂有用的化合物。发明人进一步研究了丙酮酸1,3-二酮衍生物。结果，他们证实，在2-(1,3-二氢-2H-苯并咪唑-2-基亚胺)具有苯环或噻吩环的衍生物中，取代为—SO2—R3基团的化合物具有出色的GnRH受体拮抗作用，并完成了本发明。由于本发明的化合物具有强效的GnRH受体拮抗作用，因此对于治疗性激素依赖性疾病，特别是GnRH相关疾病非常有用。此外，由于本发明的化合物在人体内具有出色的代谢稳定性和较少的药物相互作用，因此作为用于上述疾病的药物具有良好的特性。
• PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP1864976A1

  公开（公告）日：2007-12-12

  It is intended to provide a compound useful as a GnRH receptor antagonist. The inventors further investigated propane-1,3-dione derivatives. As a result, they confirmed that a compound having a benzene ring or a thiophene ring substituted with a group represented by -SO2-R3 in a propane-1,3-dione derivative having 2-(1,3-dihydro-2H-benzimidazol-2-ylidene) has an excellent GnRH receptor antagonistic effect and accomplished the present invention. Because the compound of the present invention has a potent GnRH receptor antagonistic effect, it is useful for the treatment of sex hormone-dependent diseases, particularly GnRH-related diseases. Further, because the compound of the present invention has an excellent metabolic stability in human and few drug interactions, therefore it has preferable characteristics as a pharmaceutical used for the above-mentioned diseases.

  其目的是提供一种可用作 GnRH 受体拮抗剂的化合物。发明人进一步研究了丙烷-1,3-二酮衍生物。结果，他们证实在具有 2-(1,3-二氢-2H-苯并咪唑-2-亚基)的丙烷-1,3-二酮衍生物中，具有被-SO2-R3 所代表的基团取代的苯环或噻吩环的化合物具有极好的 GnRH 受体拮抗作用，并完成了本发明。由于本发明的化合物具有强效的 GnRH 受体拮抗作用，因此可用于治疗性激素依赖性疾病，特别是 GnRH 相关疾病。此外，由于本发明的化合物在人体中具有极好的代谢稳定性，且药物相互作用少，因此作为用于治疗上述疾病的药物具有更佳的特性。